Skip to main content

Advertisement

Log in

Familial Mediterranean fever, review of the literature

  • Review Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Familial Mediterranean fever (FMF) is the most common monogenic periodic fever syndrome and characterized by recurrent episodes of fever, serositis, arthritis, dermal manifestations, and long-term renal complications. The MEFV gene was described in 1997 as the gene responsible for FMF and is inherited in autosomal recessive manner. It encodes mutated protein pyrin, an important player in the innate immune system and the component of inflammasome which leads to exaggerated inflammatory response through uncontrolled production of interleukin-1. The recent progress in molecular genetics and understanding of pathogenesis showed a more complicated picture of FMF inheritance, penetrance, and pathogenesis. The pathogenesis is not completely understood although the gene responsible for FMF has been identified. Whether the pyrin mutation effect in FMF is due to a loss of function or a gain of function is still controversial. The diagnosis is mainly clinical and the genetic testing is indicated to support it. Colchicine remains the mainstay of treatment of FMF since 1972. It decreases the attacks, improves quality of life, and prevents amyloidosis. The recent advances in genetic testing and molecular studies has led to the development of new therapies of interleukin-1 inhibitors; anakinra, canakinumab, and rilonacept.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Sönmez HE, Batu ED, Özen S (2016) Familial Mediterranean fever: current perspectives. J Inflamm Res 9:13–20

    PubMed  PubMed Central  Google Scholar 

  2. Sarı İ, Birlik M, Kasifoğlu T (2014) Familial Mediterranean fever: an updated review. European Journal of Rheumatology 1(1):21–33

    Article  PubMed  PubMed Central  Google Scholar 

  3. Kucuk A, Gezer IA, Ucar R et al (2014) Familial Mediterranean fever. Acta Med (Hradec Kralove) 57:97–104

    Article  Google Scholar 

  4. Goldfinger SE (1972) Colchicine for familial Mediterranean fever. N Engl J Med 287(25):1302

    CAS  PubMed  Google Scholar 

  5. French FMF Consortium (1997) A candidate gene for familial Mediterranean fever. Nat Genet 17(1):25–31

    Article  Google Scholar 

  6. The International FMF Consortium (1997) Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 90(4):797–807

    Article  Google Scholar 

  7. Ben-Chetrit E, Touitou I (2009) Familial Mediterranean fever in the world. Arthritis Rheum 61:1447–1453

    Article  CAS  PubMed  Google Scholar 

  8. Ozen S, Batu ED (2015) The myths we believed in familial Mediterranean fever: what have we learned in the past years? Semin Immunopathol 37(4):363–369

    Article  CAS  PubMed  Google Scholar 

  9. Sarrauste de Menthière C, Terrière S, Pugnère D, Ruiz M, Demaille J, Touitou I (2003) INFEVERS: the registry for FMF and hereditary inflammatory disorders mutations. Nucleic Acids Res 31(1):282–285

    Article  PubMed  PubMed Central  Google Scholar 

  10. Shinar Y, Obici L, Aksentijevich I et al (2012) Guidelines for the genetic diagnosis of hereditary recurrent fevers. Ann Rheum Dis 71(10):1599–1605

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Marek-Yagel D, Berkun Y, Padeh S, Abu A, Reznik-Wolf H, Livneh A, Pras M, Pras E (2009) Clinical disease among patients heterozygous for familial Mediterranean fever. Arthritis Rheum 60(6):1862–1866

    Article  CAS  PubMed  Google Scholar 

  12. Booty MG, Chae JJ, Masters SL et al (2009) Familial Mediterranean fever with a single MEFV mutation: where is the second hit? Arthritis Rheum 60(6):1851–1861

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Lachmann HJ, Sengul B, Yavuzsen TU et al (2006) Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford) 45:746–750

    Article  CAS  Google Scholar 

  14. Kalyoncu M, Acar BC, Cakar N et al (2006) Are carriers for MEFV mutations “healthy”? Clin Exp Rheumatol 24:S120–S122

    CAS  PubMed  Google Scholar 

  15. Federici S, Calcagno G, Finetti M et al (2012) Clinical impact of MEFV mutations in children with periodic fever in a prevalent western European Caucasian population. Ann Rheum Dis 71:1961–1965

    Article  PubMed  Google Scholar 

  16. Ozturk C, Halicioglu O, Coker I et al (2012) Association of clinical and genetical features in FMF with focus on MEFV strip assay sensitivity in 452 children from western Anatolia, Turkey. Clin Rheumatol 31:493–501

    Article  PubMed  Google Scholar 

  17. Marek-Yagel D, Bar-Joseph I, Pras E, Berkun Y (2009) Is E148Q a benign polymorphism or a disease-causing mutation? J Rheumatol 36:2372

    Article  PubMed  Google Scholar 

  18. Giancane G, Ter Haar NM, Wulffraat N et al (2015) Evidence-based recommendations for genetic diagnosis of familial Mediterranean fever. Ann Rheum Dis 74:635–641

    Article  CAS  PubMed  Google Scholar 

  19. De Torre-Minguela C, Mesa del Castillo P, Pelegrín P (2017) The NLRP3 and pyrin inflammasomes: implications in the pathophysiology of autoinflammatory diseases. Front Immunol 8:43

    PubMed  PubMed Central  Google Scholar 

  20. Campbell L, Raheem I, Malemud CJ, Askari AD (2016) The relationship between NALP3 and autoinflammatory syndromes. Int J Mol Sci 17(5):725

    Article  PubMed Central  Google Scholar 

  21. Abderrazak A, Syrovets T, Couchie D et al (2015) NLRP3 inflammasome: from a danger signal sensor to a regulatory node of oxidative stress and inflammatory diseases. Redox Biol 4:296–307

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Bozkurt Y, Demir A, Erman B, Gül A (2015) Unified modeling of familial Mediterranean fever and cryopyrin associated periodic syndromes. Computational and Mathematical Methods in Medicine 2015:893507

    Article  PubMed  PubMed Central  Google Scholar 

  23. Wang DQH, Bonfrate L, de Bari O, Wang TY, Portincasa P (2014) Familial Mediterranean fever: from pathogenesis to treatment. J Genet Syndr Gene Ther 5:248

    Google Scholar 

  24. Sohar E, Gafni J, Pras M et al (1976) Familial Mediterranean fever: a survey of 470 cases and review of the literature. Am J Med 43(2):227–253

    Article  Google Scholar 

  25. Capron J, Grateau G, Steichen O (2013) Is recurrent aseptic meningitis a manifestation of familial Mediterranean fever? A systematic review. Clin Exp Rheumatol 31:127–132

    PubMed  Google Scholar 

  26. Rigante D, Lopalco G, Tarantino G et al (2015) Non-canonical manifestations of familial Mediterranean fever: a changing paradigm. Clin Rheumatol 34(9):1503–1511

    Article  PubMed  Google Scholar 

  27. Ross R (1993) The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362:801–809

    Article  CAS  PubMed  Google Scholar 

  28. Kasifoglu T, Bilge SY, Sari I et al (2014) Amyloidosis and its related factors in Turkish patients with familial Mediterranean fever: a multicentre study. Rheumatology (Oxford) 53(4):741–745

    Article  Google Scholar 

  29. Lidar M, Yaqubov M, Zaks N et al (2006) The prodrome: a prominent yet overlooked pre-attack manifestation of familial Mediterranean fever. J Rheumatol 33(6):1089–1092

    PubMed  Google Scholar 

  30. Kees S, Langevitz P, Zemer D et al (1997) Attacks of pericarditis as a manifestation of familial Mediterranean fever (FMF). QJM 90:643–647

    Article  CAS  PubMed  Google Scholar 

  31. Lidar M, Kedem R, Mor A, Levartovsky D, Lan-gevitz P, Livneh A (2005) Arthritis as the sole episodic manifestation of familial Mediterranean fever. J Rheumatol 32:859–862

    PubMed  Google Scholar 

  32. Lidar M, Doron A, Barzilai A et al (2013) Erysipelas-like erythema as the presenting feature of familial Mediterranean fever. J Eur Acad Dermatol Venereol 27(7):912–915

    Article  CAS  PubMed  Google Scholar 

  33. Livneh A, Madgar I, Langevitz P (1994) Recurrent episodes of acute scrotum with ischemic testicular necrosis in a patient with familial Mediterranean fever. J Urol 151(2):431–432

    Article  CAS  PubMed  Google Scholar 

  34. Kukuy O, Livneh A, Ben-David A et al (2013) Familial Mediterranean fever (FMF) with proteinuria: clinical features, histology, predictors, and prognosis in a cohort of 25 patients. J Rheumatol 40(12):2083–2087

    Article  CAS  PubMed  Google Scholar 

  35. Van ser Hilst JC, Simon A, Drenth JP (2005) Herediaty periodic fever and reactive amyloidosis. Clin Exp Med 5(3):87–98

    Article  Google Scholar 

  36. Livneh A, Langevitz P, Zemer D et al (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40(10):1879–1885

    Article  CAS  PubMed  Google Scholar 

  37. Demirkaya E, Saglam C, Turker T et al (2016) Performance of different diagnostic criteria for familial Mediterranean fever in children with periodic fevers: results from a multicenter international registry. J Rheumatol 43(1):154–160

    Article  CAS  PubMed  Google Scholar 

  38. Ozen S, Demirkaya E, Erer B et al (2016) EULAR recommendation for the management of familial Mediterranean fever. Ann Rheum Dis 75(4):644–651

    Article  CAS  PubMed  Google Scholar 

  39. Lidar M, Yonath H, Shechter N et al (2012) Incomplete response to colchicine in M694V homozygote FMF patients. Autoimmun Rev 12(1):72–76

    Article  CAS  PubMed  Google Scholar 

  40. Gül A (2016) Approach to the patients with inadequate response to colchicine in familial Mediterranean fever. Best Pract Res Clin Rheumatol 30(2):296–303

    Article  PubMed  Google Scholar 

  41. Ozdogan H, Ugurlu S (2017) Canakinumab for the treatment of familial Mediterranean fever. Expert Rev Clin Immunol 10:1–12

    Google Scholar 

  42. Ben-Zvi I, Kukuy O, Giat E et al (2017) Anakinra for colchicine resistant familial Mediterranean fever—a randomized, double blind, placebo-controlled trial. Arthritis Rheumatol 69(4):854–862

    Article  CAS  PubMed  Google Scholar 

  43. Özçakar ZB, Özdel S, Yılmaz S et al (2016) Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis. Clin Rheumatol 35(2):441–446

    Article  PubMed  Google Scholar 

  44. Van der Hilst JC, Moutschen M, Messiaen PE, Lauwerys BR, Vanderschueren S (2016) Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature. Biologics 10:75–80

    PubMed  PubMed Central  Google Scholar 

  45. Gül A, Ozdogan H, Erer B et al (2015) Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever. Arthritis Research & Therapy 17(1):243

    Article  Google Scholar 

  46. Brik R, Butbul-Aviel Y, Lubin S et al (2014) Canakinumab for the treatment of children with colchicine-resistant familial Mediterranean fever: a 6-month open-label, single-arm pilot study. Arthritis Rheumatol 66(11):3241–3243

    Article  CAS  PubMed  Google Scholar 

  47. Hashkes PJ, Spalding SJ, Giannini EH et al (2012) Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med 157(8):533–541

    Article  PubMed  Google Scholar 

  48. Hashkes PJ, Spalding SJ, Hajj-Ali R et al (2014) The effect of rilonacept versus placebo on health-related quality of life in patients with poorly controlled familial Mediterranean fever. Biomed Res Int 2014:854842

    Article  PubMed  PubMed Central  Google Scholar 

  49. Piram M, Koné-Paut I, Lachmann HJ et al (2014) Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes. Ann Rheum Dis 73(12):2168–2173

    Article  PubMed  Google Scholar 

  50. Ozen S, Demirkaya E, Duzova A et al (2014) FMF50: a score for assessing outcome in familial Mediterranean fever. Ann Rheum Dis 73(5):897–901

    Article  PubMed  Google Scholar 

  51. Erer B, Demirkaya E, Ozen S et al (2016) What is the best acute phase reactant for familial Mediterranean fever follow-up and its role in the prediction of complications? A systematic review. Rheumatol Int 36(4):483–487

    Article  CAS  PubMed  Google Scholar 

  52. Stankovic K, Hentgen V, Fellahi S et al (2017) Concordance between CRP and SAA in familial Mediterraneanfever during attack-free period: a study of 218 patients. Clin Biochem 50(4–5):206–209

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mansour Alghamdi.

Ethics declarations

Disclosure

None.

Funding

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alghamdi, M. Familial Mediterranean fever, review of the literature. Clin Rheumatol 36, 1707–1713 (2017). https://doi.org/10.1007/s10067-017-3715-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-017-3715-5

Keywords

Navigation